CD4CAR

Phase 1Cell therapy

HHuda Salman

CD4CAR is one of 6 biologic programs targeting T - Cell Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

T - Cell LymphomaRecruiting

T - Cell LymphomaPhase 1

Recruiting

Competition

Competitive Landscape

6 competitors in T - Cell Lymphoma

#DrugCompanyPhaseTrials

Jakafi

Incyte

Phase 2

2 2

Rituxan

Roche

Phase 2

1 3

Idhifa

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

1 4

Fenretinide

EEastern Cooperative Oncology Group

Phase 1

1 5

CD4CAR

HHuda Salman

Phase 1

1 6

BMS-986369

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2042

Phase 1Recruiting

T - Cell Lymphoma

NCT03829540

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory AML as a Bridge to Allogeneic Stem Cell Transplant

Suspended·HHuda Salman·Phase 1·NCT06197672·30 enrolled

Chronic Myelomonocytic Leukemia1 trial

CD4CAR T Cell Therapy for CMML

Suspended·HHuda Salman·Phase 1·NCT06071624·30 enrolled

T - Cell Lymphoma1 trial

A Phase I, Multicenter Study of CD4- Directed Chimeric Antigen Receptor Engineered T-cells (CD4CAR) in Patients With Relapsed or Refractory CD4+ Hematological Malignancies

Recruiting·HHuda Salman·Phase 1·NCT03829540·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for CD4CAR. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CD4CAR compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CD4CAR. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Huda Salman company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: HHuda Salman

CD4CAR

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2042

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

Chronic Myelomonocytic Leukemia1 trial

T - Cell Lymphoma1 trial

References

Drug Info

Quick Facts

Related News